The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

Better biomarkers, new FDA approvals and an emerging delivery pipeline strengthen the case for Parkinson’s innovation, with AbbVie and Serina Therapeutics offering distinct investment angles.

The most compelling Parkinson’s investment story does not begin with a stock chart. It begins with a foundation helping scientists understand the disease more precisely, patients participate in research more effectively and drug developers ask better questions. The Michael J. Fox Foundation for Parkinson’s Research is doing that work. Its landmark research initiative, biological discoveries and funding commitments are building an increasingly substantial foundation for therapeutic progress. In December 2025 and January 2026 alone, the organization awarded $101 million to advance Parkinson’s research. That is more than an expression of optimism. It is optimism with a research budget. Meanwhile, commercial innovation is gathering momentum. AbbVie Inc. (NYSE: ABBV) announced FDA approval of JUVMO, its once-daily Parkinson’s treatment, on September 28, 2026. Serina Therapeutics Inc. (NYSE American: SER) is advancing an investigational approach intended to provide continuous dopaminergic stimulation in advanced Parkinson’s disease. These are different programs at very different stages, but both address a central challenge: helping patients achieve more dependable symptom control. The bullish thesis is not that Parkinson’s has suddenly become easy to treat. It is that the infrastructure supporting innovation is improving while the need for better therapies remains substantial.

The Michael J. Fox Foundation Keeps the Investment Story Grounded in Patients

The Foundation’s Parkinson’s 101 resource, which features an educational video with movement disorders neurologist Dr. Rachel Dolhun, explains the disease through its underlying biology. Parkinson’s occurs when brain cells that produce dopamine, a chemical involved in coordinating movement, stop functioning or die. Symptoms can include slowness, stiffness, tremor and difficulties with walking or balance. Non-motor symptoms, including depression, constipation, sleep problems and cognitive changes, can also affect daily life. That distinction matters. Parkinson’s is not a single symptom awaiting a single elegant solution. It is a progressive, highly individual disease requiring a range of treatment approaches. The Foundation also makes an essential point for investors and patients alike: available therapies can help manage symptoms, but there is currently no cure or established treatment that stops or slows disease progression. The opportunity for innovation therefore extends beyond improved movement control to better diagnostics, more personalized treatment and, ultimately, disease-modifying therapies. For many, that creates a broad research landscape. For families, it creates a much more practical objective: better days. The two interests can align, provided the spreadsheet remembers why it exists.

From Awareness to Research Infrastructure

The Michael J. Fox Foundation’s influence reaches well beyond public awareness. Launched in 2010, its flagship PPMI study collects information over time to understand how Parkinson’s begins and changes. In 2026, the Foundation renamed the study the Parkinson’s Precision Medicine Initiative, reflecting its expanding role in connecting biological understanding with more individualized approaches to research and treatment. More than 40 public, private and nonprofit partners support the initiative. The financial commitment is substantial. In a May 2026 announcement, the Foundation reported investing more than $800 million over the preceding 15 years to build one of the world’s most comprehensive Parkinson’s datasets. That infrastructure matters because drug development depends on more than discovering a promising molecule. Researchers also need to identify appropriate participants, understand differences among patients and measure whether a treatment is producing a meaningful effect. The Foundation has documented how companies use PPMI data to guide trial eligibility, predictive modeling and study design. Better research tools do not guarantee successful medicines, but they can improve the quality of the questions clinical trials are designed to answer. For an industry accustomed to expensive uncertainty, better questions are a valuable asset.

Biomarkers Could Make Parkinson’s Research More Precise

One of the Foundation’s most important contributions is helping move Parkinson’s research beyond symptoms alone. In 2023, PPMI scientists announced a test that detects abnormal alpha-synuclein activity, a biological hallmark associated with Parkinson’s. The Foundation describes this discovery as a turning point in how researchers understand the disease and pursue prevention strategies. Its Parkinson’s 101 resource explains that the alpha-synuclein seed amplification assay can detect misfolded protein in spinal fluid, including in some high-risk individuals who have not yet developed clinical symptoms. Use remains largely concentrated in clinical trials, and broader application will require further development, including less invasive testing approaches. The investment relevance is straightforward: a more biologically defined disease could support more precisely designed trials. The Foundation’s biomarker funding program explicitly seeks tools that improve classification and staging, identify distinct biological subgroups and help predict progression in movement and cognition. Those capabilities could help developers match investigational treatments with the patients most relevant to a particular mechanism. This is not the same as having a cure. It is a potentially better map for finding one.

AbbVie’s JUVMO Approval Adds a New Commercial Catalyst

AbbVie’s JUVMO approval gives the research narrative a tangible commercial counterpart. JUVMO, also known as tavapadon, is approved for adults with Parkinson’s disease and can be taken once daily, with or without levodopa. According to AbbVie, it is the first and only approved selective D1/D5 receptor agonist for this indication, offering a different receptor-targeting approach from commonly used dopamine agonists that primarily target D2/D3 receptors. The company expects U.S. availability in October 2026. The approval rests on the Phase 3 TEMPO clinical program, which evaluated tavapadon in early Parkinson’s and as an addition to levodopa in patients experiencing motor fluctuations. In TEMPO-3, patients receiving JUVMO plus levodopa increased daily “on” time without troublesome dyskinesia by 1.7 hours, compared with 0.6 hours for placebo plus levodopa at week 26. That represents a 1.1-hour advantage over the comparator. “On” time refers to periods of better symptom control, while dyskinesia describes involuntary movements that can complicate treatment. An extra hour of more dependable movement may look modest in a financial model. In daily life, it can be considerably less modest. The Foundation’s connection to this milestone is explicit. AbbVie’s announcement includes comments from Brian Fiske, the Foundation’s chief scientist, emphasizing that each approval helps build the diverse treatment pipeline needed to address the Parkinson’s community’s unmet needs. That perspective should not be confused with a company or product endorsement: the Foundation states that it does not advocate, endorse or promote specific therapies or companies. JUVMO also carries meaningful safety considerations, including risks involving low blood pressure, hallucinations, unusual urges and dyskinesia. Its approval expands symptom-management options; it does not establish disease modification.

Serina Therapeutics Offers a Different Kind of Parkinson’s Opportunity

The smaller-company side of the story belongs to Serina Therapeutics (NYSE American: SER), whose SER-252 program targets a different problem from JUVMO. SER-252 is an investigational apomorphine therapy developed using Serina’s proprietary POZ polymer platform. The technology is designed to control drug loading and release following subcutaneous administration, with the objective of providing continuous dopaminergic stimulation. The scientific proposition is that optimizing delivery of an established therapeutic agent could produce a more useful treatment profile. That proposition still requires clinical validation. Serina reported on September 9, 2026, that an independent Safety Monitoring Committee had completed a blinded review of the first cohort in its Phase 1b study and recommended advancement to Cohort 2. The first cohort enrolled eight patients with Parkinson’s disease and motor fluctuations at the lowest dose level in the single-ascending-dose portion of the trial. The company expects topline results from the single-ascending-dose portion in the first half of 2027. The study is evaluating safety, tolerability, pharmacokinetics and exploratory measures of clinical activity. That creates a defined catalyst window, not a predetermined outcome. Although Serina describes the program as a “registrational” study, many should keep the development stage in focus. It remains a Phase 1b trial. Progression to another dose cohort is an operational milestone, not proof of efficacy or an assurance of eventual approval. The attractive possibility is a differentiated delivery approach in a disease where consistency matters. The necessary discipline is remembering that a promising platform and a successful medicine are not interchangeable terms.

A Broader Treatment Landscape Supports the Innovation Thesis

AbbVie and Serina are not operating in isolation. Recent approvals show that Parkinson’s innovation can take several forms, including new receptor targeting, improved oral formulations and continuous infusion:

• Amneal Pharmaceuticals Inc. (Nasdaq: AMRX) received FDA approval for CREXONT in August 2024. The oral carbidopa/levodopa formulation combines immediate-release granules with extended-release pellets to support rapid onset and longer-lasting activity.
• Supernus Pharmaceuticals Inc. (Nasdaq: SUPN) announced FDA approval of ONAPGO in February 2025 as a subcutaneous apomorphine infusion device for motor fluctuations in adults with advanced Parkinson’s disease.
• AbbVie (NYSE: ABBV) is adding JUVMO’s selective D1/D5 approach, while Serina (NYSE American: SER) is testing its investigational polymer-enabled apomorphine program.

These therapies and candidates should not be ranked against one another using results from separate trials. Their mechanisms, delivery methods, development stages and studied populations differ. Collectively, however, they support a constructive interpretation: developers are pursuing multiple ways to address the gaps left by existing treatment. Parkinson’s does not need a winner-take-all contest. It needs a deeper bench.

What Many Should Watch Next

The most useful investment framework separates research progress, commercial execution and clinical risk.

AbbVie: Turning Approval Into Adoption

For AbbVie (NYSE: ABBV), the next chapter is commercialization. Its planned October 2026 U.S. availability moves JUVMO from a development asset toward real-world use. Investors can watch physician adoption, patient access and how the treatment fits into existing care pathways. Approval opens the door; execution determines how much business walks through it,

Serina: Evidence Before Extrapolation

For Serina (NYSE American: SER), the key milestones are dose-escalation progress and the planned first-half 2027 single-ascending-dose results. Safety, drug exposure and exploratory clinical observations will help determine whether the delivery thesis deserves greater confidence. Financing also remains material: the company’s disclosures identify additional capital requirements and going-concern risk among its uncertainties.

The Foundation: Better Tools for the Entire Field

For The Michael J. Fox Foundation, the opportunity is broader than any single product. Its research funding, PPMI infrastructure and biomarker initiatives can support scientific progress across multiple development programs. That is the central reason the Foundation belongs at the heart of this story rather than in a charitable footnote. Many seeking broader biotechnology exposure can also research the iShares Biotechnology ETF (Nasdaq: IBB) and the State Street SPDR S&P Biotech ETF (NYSE Arca: XBI). These are sector funds, not dedicated Parkinson’s investments, and should not be treated as direct proxies for the programs discussed here.

The Most Durable Bull Case Starts With Better Science

The Parkinson’s opportunity is becoming more compelling because several kinds of progress are converging. The Michael J. Fox Foundation is helping build the biological understanding and research infrastructure needed for better drug development. AbbVie’s JUVMO approval adds a differentiated treatment option. Amneal and Supernus demonstrate the continuing importance of formulation and delivery innovation. Serina offers an earlier-stage test of whether polymer-enabled delivery can contribute another useful approach. None of that eliminates clinical failure, reimbursement challenges, competition or financing risk. It does make the sector more interesting than a simple collection of speculative promises. For many, the strongest thesis is not “a cure is around the corner.” It is that better science, broader treatment options and measurable development milestones are creating more opportunities to generate value. For patients, the measure of that value is ultimately simpler: whether innovation makes everyday life better.

The Sources

1. The Michael J. Fox Foundation: What Is Parkinson’s Disease?
   Overview of Parkinson’s biology, motor and non-motor symptoms, available treatments and emerging diagnostic tools.
2. The Michael J. Fox Foundation: PPMI, the Study That’s Changing Everything
   Background on the Parkinson’s Precision Medicine Initiative, its research mission and its role in advancing biological understanding of Parkinson’s.
3. The Michael J. Fox Foundation: Landmark Parkinson’s Study Enters a New Era of Precision Medicine
   May 2026 announcement describing PPMI’s evolution and the Foundation’s investment in its research infrastructure.
4. The Michael J. Fox Foundation: Parkinson’s Progression Markers Initiative
   Explanation of PPMI’s dataset, biosample resources and contributions to scientific discovery and biomarker validation.
5. The Michael J. Fox Foundation: PPMI Biofluid Biomarkers Program
   Research-funding priorities for biomarkers that could improve disease classification, staging and understanding of progression.
6. The Michael J. Fox Foundation: What We Fund, Seeing, Measuring and Targeting Parkinson’s Disease
   April 2026 report covering $101 million awarded in December 2025 and January 2026 to advance Parkinson’s research.
7. The Michael J. Fox Foundation: Parkinson’s Biomarkers, Critical Tools for Revolutionizing Research
   Background on Parkinson’s biomarkers and the alpha-synuclein seed amplification assay.
8. AbbVie: U.S. FDA Approves JUVMO for Parkinson’s Disease
   Primary company announcement covering JUVMO’s approval, mechanism, Phase 3 TEMPO results, planned availability and safety information. Company ticker: NYSE: ABBV.
9. Reuters: U.S. FDA Approves AbbVie’s Drug for Parkinson’s Disease
   Independent reporting on the regulatory approval of AbbVie’s Parkinson’s treatment. Company ticker: NYSE: ABBV.
10. Serina Therapeutics: Cohort 1 Observations From SER-252 Study and Advancement to Cohort 2
    September 9, 2026 clinical update covering safety-monitoring review, dose escalation and the expected timing of single-ascending-dose results. Company ticker: NYSE American: SER.
11. Serina Therapeutics: First Patient Enrolled in Phase 1b SER-252 Trial
    Description of the investigational therapy, trial objectives and development risks. Company ticker: NYSE American: SER.
12. Serina Therapeutics: Full-Year 2025 Financial Results and Business Highlights
    Background on the POZ polymer platform, SER-252 development and company financial disclosures. Company ticker: NYSE American: SER.
13. Amneal Pharmaceuticals: FDA Approval of CREXONT
    August 7, 2024 announcement covering the approval of extended-release carbidopa/levodopa capsules. Company ticker: Nasdaq: AMRX..
14. Supernus Pharmaceuticals: FDA Approval of ONAPGO
    February 4, 2025 announcement covering subcutaneous apomorphine infusion for motor fluctuations in adults with advanced Parkinson’s disease. Company ticker: Nasdaq: SUPN.
15. iShares: iShares Biotechnology ETF
    Official fund page for broader biotechnology-sector exposure. ETF ticker: Nasdaq: IBB,
16. Yahoo Finance: State Street SPDR S&P Biotech ETF
    Fund profile and market information for the biotechnology ETF. ETF ticker: NYSE Arca: XBI,